{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:56:14Z","timestamp":1787313374714,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone deficiency (PGHD).<\/jats:p>\n                  <jats:p>Lonapegsomatropin, a long-acting GH therapy (LAGH), was approved by the United States Food and Drug Administration (FDA) in August 2021 for the treatment of PGHD and has also been approved in other regions of the world. Somatrogon was approved for the treatment of PGHD beginning in some regions beginning in late 2021. Somapacitan was approved by the FDA for the treatment of Adult GHD in August 2020. The phase III clinical trial of somapacitan for the treatment of PGHD has been completed and demonstrated non-inferiority of somapacitan to DGH.<\/jats:p>\n                  <jats:p>New LAGH products may improve patient adherence, quality of life and clinical outcomes, particularly in patients with poor adherence to daily GH injections in the future. With the availability of new LAGH products, clinicians will need to identify the best candidates for LAGH therapy and understand how to monitor and adjust therapy. Long-term surveillance studies are needed to demonstrate adherence, efficacy, cost-effectiveness and safety of LAGH preparations and to understand how the non-physiological pharmacokinetic and pharmacodynamic profiles following administration of each LAGH product relate to short- and long-term safety and efficacy of LAGH therapy.<\/jats:p>","DOI":"10.3389\/fendo.2022.980979","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T05:10:49Z","timestamp":1661145049000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["What do we do now that the long-acting growth hormone is here?"],"prefix":"10.3389","volume":"13","author":[{"given":"Bradley S.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.02.013","article-title":"Association of daily growth hormone injection adherence and height among children with growth hormone deficiency","volume":"28","author":"Loftus","year":"2022","journal-title":"Endocrine Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.S3.512","article-title":"Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: the national cooperative growth study experience","volume":"102","author":"August","year":"1998","journal-title":"Pediatrics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.17458\/per.vol16.2018.25yearsghdata","article-title":"National cooperative growth study: 25 years of growth hormone data, insights, and lessons for future registries","volume":"16","author":"Bell","year":"2018","journal-title":"Pediatr Endocrinol Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01189","article-title":"Safety outcomes during pediatric GH therapy: Final results from the prospective GeNeSIS observational program","volume":"104","author":"Child","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000508190","article-title":"Safety and effectiveness of omnitrope r, a biosimilar recombinant human growth hormone: More than 10 years' experience from the PATRO children study","volume":"93","author":"Pfaffle","year":"2020","journal-title":"Hormone Res Paediatrics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2284","article-title":"Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database","volume":"91","author":"Reiter","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2015.08.006","article-title":"Attaining genetic height potential: Analysis of height outcomes from the ANSWER program in children treated with growth hormone over 5 years","volume":"25","author":"Ross","year":"2015","journal-title":"Growth Hormone Igf Res"},{"key":"B8","article-title":"Growth hormone dosage associated with change in height standard deviation score over 4 years of treatment by age in pediatric patients with isolated growth hormone deficiency (IGHD)","volume-title":"Results from the ANSWER program","author":"Miller","year":"2015"},{"key":"B9","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-acting growth hormone preparations - current status and future considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab529","article-title":"Weekly lonapegsomatropin in treatment-naive children with growth hormone deficiency: The phase 3 heiGHt trial","volume":"106","author":"Thornton","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac220","article-title":"Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: A phase 3 study","volume":"107","author":"Deal","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","volume-title":"Once-weekly somapacitan is effective and well tolerated in children with GHD: a randomized phase 3 trial","author":"Miller","year":"2022"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac217","article-title":"Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results","volume":"107","author":"Maniatis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"09","DOI":"10.1159\/000524003","article-title":"Switching to weekly lonapegsomatropin from daily somatropin in children with growth hormone deficiency: The fliGHt trial","volume":"9","author":"Maniatis","year":"2022","journal-title":"Hormone Res Paediatrics"},{"key":"B15","volume-title":"Safety and efficacy of treatment with lonapegsomatropin in children with growth hormone deficiency at week 130 in the enliGHten trial","author":"Thornton","year":"2022"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0748","article-title":"MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a phase 2 study in growth hormone-deficient adults","volume":"176","author":"Strasburger","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.1279","article-title":"OR10-06 somatrogon growth hormone in the treatment of pediatric growth hormone deficiency: Results of the pivotal pediatric phase 3 clinical trial","volume":"4","author":"Deal","year":"2020","journal-title":"J Endocrine Soc"},{"key":"B18","unstructured":"OPKO and pfizer announce positive phase 3 top-line results for somatrogon, an investigational long-acting human growth hormone to treat children with growth hormone deficiency2019"},{"key":"B19","unstructured":"Pfizer and OPKO\u2019s once-weekly NGENLA\u2122 (somatrogon) injection receives marketing authorization in European union for treatment of pediatric growth hormone deficiency2022"},{"key":"B20","unstructured":"ParkB\n          FDA Denies approval of long-acting pediatric growth hormone therapy2021"},{"key":"B21","article-title":"Growth outcomes from the phase 2 and phase 3 studies of once weekly somatrogon vs daily genotropin in pediatric patients with growth hormone deficiency","volume-title":"Comparisons with published literature and an international growth study database","author":"Zadik","year":"2022"},{"key":"B22","unstructured":"A research study in children born small and who stayed small. treatment is somapacitan once a week compared to norditropin\u00ae once a day2019"},{"key":"B23","unstructured":"A research study in children with a low level of hormone to grow. treatment is somapacitan once a week compared to norditropin\u00ae once a day (REAL4)2019"},{"key":"B24","volume-title":"Once-weekly somapacitan in growth hormone deficiency: 4-year efficacy and safety results from REAL 3, a randomized controlled phase 2 trial","author":"Savendahl","year":"2022"},{"key":"B25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1210\/clinem\/dgz310","article-title":"Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3","volume":"29","author":"Savendahl","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa775","article-title":"Optimal monitoring of weekly IGF-I levels during growth hormone therapy with once-weekly somapacitan","volume":"106","author":"Juul Kildemoes","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"bvab168","DOI":"10.1210\/jendso\/bvab168","article-title":"Average IGF-1 prediction for once-weekly lonapegsomatropin in children with growth hormone deficiency","volume":"6","author":"Lin","year":"2022","journal-title":"J Endocrine Soc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3547","article-title":"Long-acting c-terminal peptide-modified hGH (MOD-4023): Results of a safety and dose-finding study in GHD children","volume":"102","author":"Zelinska","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab016","article-title":"The use of IGF-I to monitor long-acting growth hormone therapy-timing is an art","volume":"106","author":"Bidlingmaier","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults","volume":"174","author":"Allen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0111","article-title":"Growth hormone research society perspective on the development of long-acting growth hormone preparations","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000080760","article-title":"The role of insulin-like growth factor I monitoring in growth hormone-treated children","author":"Park","year":"2004","journal-title":"Hormone Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0204","article-title":"Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study","volume":"92","author":"Cohen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3776","article-title":"A randomized phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency","volume":"102","author":"Chatelain","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1210\/clinem\/dgz310","article-title":"Once-weekly somapacitan vs daily GH in children with GH deficiency: Results from a randomized phase 2 trial","volume":"105","author":"Savendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1002","article-title":"Risk of neoplasia in pediatric patients receiving growth hormone therapy\u2013a report from the pediatric endocrine society drug and therapeutics committee","volume":"100","author":"Raman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000520812","article-title":"Evolution and future of growth plate therapeutics","volume":"94","author":"Allen","year":"2021","journal-title":"Hormone Res Paediatrics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000489262","article-title":"Once-weekly administration of sustained-release growth hormone in Korean prepubertal children with idiopathic short stature: A randomized, controlled phase II study","volume":"90","author":"Hwang","year":"2018","journal-title":"Hormone Res Paediatrics"},{"key":"B39","unstructured":"A research study to compare somapacitan once a week with norditropin\u00ae once a day in children who need help to grow (REAL 8)2022"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S84597","article-title":"Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia b","volume":"7","author":"Djambas Khayat","year":"2016","journal-title":"J Blood Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s7494","article-title":"Exenatide once weekly: clinical outcomes and patient satisfaction","volume":"4","author":"Jose","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1182\/blood-2019-128083","article-title":"Patterns and predictors of emicizumab adherence in people with hemophilia","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S99732","article-title":"Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany","volume":"9","author":"Qiao","year":"2016","journal-title":"Diabetes Metab Syndrome Obes Targets Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.17458\/per.vol16.2018.mr.monitoringrhghsafety","article-title":"Monitoring rhGH safety: rhGH registries, SAGhE and future needs","volume":"16","author":"Miller","year":"2018","journal-title":"Pediatr Endocrinol Rev"},{"key":"B45","volume-title":"Pfizer registry of outcomes in growth hormone RESearch (PROGRES): a multi-country, non-interventional, prospective, cohort study of patients receiving human growth hormone treatments under routine clinical care","author":"Geffner","year":"2022"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.980979\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T05:11:04Z","timestamp":1661145064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.980979\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":45,"alternative-id":["10.3389\/fendo.2022.980979"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.980979","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"article-number":"980979"}}